Author

H.J. Droogendijk

Observed names: H Droogendijk, H. Droogendijk

Institution: Bravis Ziekenhuis

Observed institutions: Erasmus MC, Bravis Ziekenhuis

OpenAlex ID: A5022058782

Imatinib Mesylate in the Treatment of Systemic Mastocytosis, a Phase I/II Trial.

2004 · H.J. Droogendijk, J.C. Kluin-Nelemans, et al. · Blood · 9

352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)

2024 · N. Wortelboer, S. Kent, et al. · Annals of Oncology · 2

70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study

2022 · M. De With, J. Knikman, et al. · Annals of Oncology · 1

EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)

2024 · S Kent, N Wortelboor, et al. · Value in Health

2015 · M. Akcakaya, S. Alers, et al. · Elsevier eBooks

Gravity gradiometer system for Earth Exploration

2009 · R. Cuperus, F.J. Flokstra, et al. · University of Twente Research Information

Works count: 6

Citation count: 12

H-index: 2

I10-index: